about Carol A. Dutch, MIEM/MBA:
Carol A. Dutch is Senior Director, Patient Engagement at Lumos Pharma. Over the course of her 25-year career, Ms. Dutch has led successful global launches of ultra-rare products (Carbaglu®, Normosang ®, Orfadin ®,Cystagon ®, Cystadane ®, Wilzin ® ) and developed innovative awareness programs (CheckAmmonia.com, ScreenCreatine.org) Carol firmly believes that building programming that circularly connects “patients to physicians to pharma to scientists to patients” is critical for rare disease drug development and has implemented this philosophy when partnering with professional societies and patient advocacy organizations. Prior to joining Lumos, Ms. Dutch worked in the Recordati Group, initially setting up and managing Orphan Europe Italy and then more recently in the US at Recordati Rare Diseases, Inc. in marketing and advocacy roles. She is actively involved with many disease patient organizations (Association for Creatine Deficiencies (ACD), National Urea Cycle Disorders Foundation (NUCD), American Porphyria Foundation (APF) as well as the umbrella organizations of Global Genes, the National Organization of Rare Disorders (NORD) and Rare Disease Legislative Advocates (RDLA).
Ms. Dutch holds a Master’s degree in International Economic Management (MIEM/MBA) from the SDA Bocconi University, Milan, Italy and a B.S. from the University of Southern California (USC) in Business Administration.